Companies Must Refine Patient Selection In Studies To Maximize Payment
This article was originally published in The Gray Sheet
Executive SummaryIn the post-health-care-reform environment, device and drug companies must carefully consider what types of patients they include in their clinical trials to maximize chances for reimbursement, according to analysts from Parexel Consulting
You may also be interested in...
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.